Title: Whither Robotic Colorectal Surgery?

Authors:
Julie Flynn, MBBS, FRACS*
Department of Surgery, Epworth Healthcare, Richmond
Division of Cancer Surgery, Peter MacCallum Cancer Centre

Jose T. Larach, MD, MSChCP
Division of Cancer Surgery, Peter MacCallum Cancer Centre

Satish Warrier, MBBS, FRACS
Department of Colorectal Surgery, Alfred health

Alexander Heriot, MD, FRACS
Division of Cancer Surgery, Peter MacCallum Cancer Centre

*Corresponding author:
Julie Flynn
Department of Surgery, Epworth Healthcare, Bridge Rd, Richmond, 3121
Jafly1@gmail.com
+61 470 415 567

Disclosures:
J Flynn No conflicts
T Larach Educational grant funded by Intuitive Surgical

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ans.16067

This article is protected by copyright. All rights reserved.
S Warrier   Honorarium for proctoring robotic cases
A Heriot     No conflicts
Whither Robotic Colorectal surgery?

Robotic colorectal surgery remains controversial. With outcomes similar to laparoscopy, the costs are seen as prohibitive by many. Yet the achievement of equal outcomes so early in its evolution promises greater benefits to come, for patients as well as surgeons due to better ergonomics. Costs, meanwhile, should reduce as technology advances and alternative robotic platforms enter the market, pushing more competitive pricing.

Robotic-assisted surgery using the da Vinci© surgical system (Intuitive Surgical, CA, USA) has been widely adopted in Australia since its introduction in 2003 (1). As the technology has evolved, its applications have moved well beyond its original roots in urology, into other surgical specialties.

The NSW Ministry of Health and the Victorian Department of Health and Human Services (DHHS) commissioned a review of robotic-assisted surgery in 2018 (2). The report concluded that ‘robot-assisted surgery is safe and effective’ but there is ‘little or no difference in outcomes.’

The subsequent DHHS policy position (3) states that the costs of the robotic platform ‘do not appear to be offset by benefits to patients or savings to the health system’. Therefore, DHHS ‘does not support further adoption of robot-assisted surgery but recommends ongoing use of existing robots within an evaluation framework’ and recommends ‘further development of training and credentialing standards.’

This may induce a sense of déjà vu for some. In the 1990’s, laparoscopy sparked similar debate. The first laparoscopic cholecystectomy in Australia took six hours (4). As surgeons
gained experience with the new technique, increased bile duct injuries were reported (5). Referrals to biliary units increased and longer operative times reduced the number of cases performed (5). A 1990 report commented on increased costs and lack of evidence for clinical benefits (6). Sound familiar?

Most studies comparing robotic to laparoscopic colorectal surgery have found equal outcomes in terms of resection margins, adequate TME, lymphadenectomy and complication rates. Some studies have found benefits in recovery and long-term function after robotic surgery (7, 8). The first large randomised controlled trial comparing robotic to laparoscopic rectal surgery, the ROLARR trial (7) found no difference in overall conversion rates. However, subgroup analysis showed lower conversion rates in males, obese patients and low tumours. This may reflect greater benefits of a robotic assisted approach with more complex surgery. Outside of clinical trials, surgeons are more likely to attempt and complete more complex colorectal work with a robotic platform compared with a laparoscopic approach (9).

The surgeons in the ROLARR trial had, on average, performed more than double the number of laparoscopic rectal resections than robotic. They had extensive laparoscopic colorectal experience, yet unlike early laparoscopic surgeons, they achieved equivalent outcomes very early in their robotic experience. Further investment into laparoscopy led to more refined techniques and better equipment. The same evolution is already occurring in robotic surgery.

Conversely, it should be remembered that a technology dependent platform mandates close relationships between industry and clinicians. Potential bias and conflict of interest must be a consideration when interpreting study results, with evidence showing poor declaration of
conflicts by authors (10) and correlation between industry funding and findings in favour of robotic surgery (11). Oversight is essential.

Robotic surgery is also much kinder to the surgeon. Sixty-eight percent of surgeons report generalised pain (12), with minimally invasive surgeons at far greater risk of pain, fatigue and numbness. Musculoskeletal symptoms are linked to reduced performance, burnout and earlier retirement (13).

Lower physical symptom rates are reported in robotic surgery (14). When performing identical simulator tasks laparoscopically and robotically, surgeons showed significant reductions in both cognitive and physical stress parameters as well as improved performance using the robot (15). Surgeons endure physical discomfort and injury to give their patients the best possible treatment, however can this be minimised?

Robotic surgery has particular benefits for training, allowing closer supervision and more precise mentor engagement. A procedure can be undertaken on a simulator first and then using a dual console, with direct input and control by the instructor, collecting real time training data for further analysis.

Early in its evolution, robotic colorectal surgery has already proven safe, with at least equal results to laparoscopy. New robotic platforms are likely to increase the uptake and application of robotics and reduce costs and operative time. Patient and surgeon focused evaluation and assessment is essential to ensure safety and benefit, however continuing to invest in the robotic field should be seen as a worthy investment in the future of surgery.
References:

2. Review of robot-assisted surgery.

This article is protected by copyright. All rights reserved.